Related Experiment Video
Updated: Aug 14, 2026
Rodent Model of Intestinal Ischemia-Reperfusion Injury via Occlusion of the Superior Mesenteric Artery
Published on: October 20, 2023
[Mesenteric infarction. 17-year retrospective study]
Abstract:
Almost half of our patients admitted with mesenteric infarction (MI) (n = 81) were inoperable. In the group (n = 44) who underwent curative therapy, 45% have survived, 32% died of recurrent MI and 23% from causes other than intestinal ischemia. In view of this high rate of recurrence our therapeutic strategy in MI needs to be reconsidered. Postischemic vasoconstriction may be the main cause of the progression of mesenteric ischemia despite apparently curative treatment. Selective injection of vasodilators in the superior mesenteric artery may improve prognosis.
Insights
Mesenteric infarction (MI) treatment needs reconsideration due to high recurrence rates. Selective vasodilator injection may improve outcomes by counteracting post-ischemic vasoconstriction.
Area of Science:
- Gastroenterology
- Vascular Surgery
- Critical Care Medicine
Context:
- Mesenteric infarction (MI) is a critical condition with high mortality.
- A significant portion of patients admitted with MI are inoperable.
- Current curative therapies for MI have a high recurrence rate.
Purpose:
- To evaluate the outcomes of patients treated for mesenteric infarction.
- To identify factors contributing to the high recurrence rate of MI.
- To propose a revised therapeutic strategy for MI.
Summary:
- Of 81 patients with MI, 44 underwent curative therapy, with a 45% survival rate.
- 32% of treated patients died from recurrent MI, and 23% from other causes.
- High recurrence suggests post-ischemic vasoconstriction may drive progression.
Impact:
- Findings necessitate a re-evaluation of current therapeutic strategies for MI.
- Selective intra-arterial vasodilator injection is proposed to improve prognosis.
- This approach may mitigate progression of mesenteric ischemia and reduce mortality.
